Chimeric antigen receptor T-cell therapy for acute lymphocytic leukaemia: where are we in 2020?-Reference-Cited by-同舟云学术

Chimeric antigen receptor T-cell therapy for acute lymphocytic leukaemia: where are we in 2020?

Published:2020-11 Issue:11 Volume:7 Page:e778-e779
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Laetsch Theodore W

Publisher

Elsevier BV

Subject

Hematology

Reference10 articles.

1. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia;Grupp;N Engl J Med,2013

2. Engineering strategies to overcome the current roadblocks in CAR T cell therapy;Rafiq;Nat Rev Clin Oncol,2020

3. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphoblastic leukaemia: a systematic review and meta-analysis;Anagnostou;Lancet Haematol,2020

4. Molecular detection of minimal residual disease precedes morphological relapse and could be used to identify relapse in pediatric and young adult B-cell acute lymphoblastic leukemia patients treated with tisagenlecleucel;Pulsipher;Blood,2018

5. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia;Fraietta;Nat Med,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antigen-Dependent Inducible T-Cell Reporter System for PET Imaging of Breast Cancer and Glioblastoma;Journal of Nuclear Medicine;2022-08-18

2. Antigen-dependent inducible T cell reporter system for PET imaging of breast cancer and glioblastoma;2022-02-16

3. Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?;Frontiers in Pediatrics;2022-01-25